The American Society of Clinical Oncology (ASCO) and the Pancreatic Cancer Action Network announced a partnered effort to educate physicians about treatment strategies for pancreatic cancer. From a joint collaboration between ASCO University®, the Pancreatic Cancer Action Network, and The ASCO Cancer Foundation®, the 2011 ASCO Tumor Board: Pancreatic Cancer highlights the current treatment strategies and novel therapeutics that exist for this disease, the fourth leading cause of cancer death in the United States.
Seventy five percent of patients with pancreatic cancer die within the first year of diagnosis and only six percent survive more than five years. As part of this ASCO University tumor board series on pancreatic cancer treatments, the program will focus on radiotherapy options and new chemotherapy regimens.
The tumor board pairs pancreatic cancer experts and technology through ASCO University, ASCO's online physician education forum, to create an open environment for oncology professionals to learn about treatment approaches for this disease. Doctors who log on to the 2011 ASCO Tumor Board: Pancreatic Cancer, will be able to walk through a patient case presented by leading experts in pancreatic cancer care who represent both ASCO and the Pancreatic Cancer Action Network and also contribute to the discussion. The case presentation and discussion is led by Eileen O'Reilly, MD, Medical Oncologist from Memorial Sloan-Kettering Cancer Center and Christopher Crane, MD, Radiation Oncologist from The University of Texas M. D. Anderson Cancer Center. Both serve as members of the Pancreatic Cancer Action Network Medical Advisory Council.
"Pancreatic cancer remains a challenge and we need to work together as a physician community in order to improve outcomes for our patients," said Ronald Blum, MD, Chair of ASCO's Education Production Subcommittee. "This Tumor Board on ASCO University allows us to interact and learn about the newest technologies and therapies for treating our patients with pancreatic cancer."
"The Pancreatic Cancer Action Network is proud to participate in the continuing education of healthcare professionals who treat pancreatic cancer patients," stated Julie Fleshman, President and CEO of the Pancreatic Cancer Action Network. "We are thrilled to collaborate with ASCO on this important project and expand our outreach efforts to oncologists and healthcare professionals to ensure the most cutting edge treatment is available."
The case presentation for Pancreatic Cancer Tumor Board will be available for one year, while the online discussion forum will be open through Feb 18th. Once closed, the key discussion points noted in the forum will be summarized and made available in the module containing the presentation. Physicians can log on to the 2011 ASCO Tumor Board: Pancreatic Cancer for free by visiting here.
Source:
American Society of Clinical Oncology (ASCO)
ASCO Cancer Foundation
Pancreatic Cancer Action Network
No comments:
Post a Comment